Melanoma
From the Journals
Few new cancer drugs replace current standards of care
Newer drugs could benefit patients but could increase the cost of care.
Latest News
FDA approves new immunotherapy combo for metastatic melanoma
Approval is based on findings that show median progression-free survival of 10.1 months.
Latest News
Adverse skin effects of cancer immunotherapy reviewed
“The desirable, immune-mediated oncologic response is often achieved at the cost of immune-related adverse events (irAEs) that may potentially...
Latest News
Ways to lessen toxic effects of chemo in older adults
Three recent high-quality randomized trials evaluated the use of geriatric assessment in older adults with cancer.
Latest News
Complex link between gut microbiome and immunotherapy response in advanced melanoma
Previous studies have identified the gut microbiome as “a potential biomarker of response as well as a therapeutic target” in melanoma and other...
Latest News
High early recurrence rates with Merkel cell carcinoma
Approximately 95% of all recurrences happened within 3 years of the initial diagnosis in the prospective cohort study.
Latest News
Why dermatologists should support artificial intelligence efforts
“I really do believe this is going to be the future,” Dr. Vishal A. Patel said.
Diminutio
“I didn’t want to meet you.” Dispelling myths about palliative care
This is the first installment of “Diminutio,” a column by Sarah D’Ambruoso, NP, a palliative care nurse in oncology. Today, she shares stories...
Latest News
Medicare NCDs hinder access to cancer biomarker testing for minorities
Failure to expand Medicare benefits widens disparities in biomarker testing. Study authors say additional efforts are needed to ensure equitable...
Latest News
Pioneering test predicts return of malignant melanoma
The test will aid clinicians to identify genuinely low-risk patients diagnosed with an early-stage melanoma, the study’s senior author said.
From the Journals
U.S. cancer deaths continue to fall, especially lung cancer
There has been an overall decline of 32% in cancer deaths as of 2019.